Researchers explored the effects of developing ICI-related colitis on patients treated with ipilimumab as monotherapy and dual therapy for advanced melanoma.
Overall incidence rate six times higher for patients aged 40 years or older versus younger than 40 years, but increase in CTCL rate significantly higher for those younger than 40 years.
Researchers sought to determine the effect of delays in surgical treatment delays of 1 to 5 months on overall and disease-specific mortality in patients with melanoma.
Adding T-VEC to pembrolizumab does not improve survival in patients with advanced melanoma, a phase 3 study suggests.
Number of new cases, deaths, and DALYs attributable to NMSC expected to increase at least 1.5-fold by 2044.